News & Events
April 21, 2024 to April 24, 2024 ● Revere Hotel Boston Common, Boston
May 14, 2024 to May 17, 2024 ● Hynes Convention Center, Boston
November 12, 2024 to November 14, 2024 ● Park Plaza Hotel, Boston
It is with heavy hearts that we announce the passing of one of the founders of Organix, Peter Meltzer.
Peter Meltzer passed away on January 25, 2024, after a difficult time battling Alzheimer’s.
Peter was an exceptional chemist, scientist, and businessman. In 1986 along with two others; Raj Razdan and Howard Sard; they founded Organix. Peter had a vision of a CRO in the Boston area that would serve the Pharmaceutical Industry. At the time there was only one large chemistry company and that was not even a pharma company. Through his and the other founder’s vision they grew Organix to be one of the premier boutique chemistry CROs.
Peter earned his Masters and Doctorate Degree in Organic Chemistry at the University of the Witwatersrand (Wits) South Africa. After graduating he then moved to the Boston area where he took up a postdoctoral research position at MIT under Sir Jack Baldwin. When Sir Jack relocated his group back to the UK Peter decided to stay and started work in the chemistry industry. Peter’s scientific career resulted in over 100 publications and >20 patents. Peter was most proud of his work towards the treatment of drug abuse, specifically cocaine abuse. He had many grants and contracts with the National Institute of Drug Abuse (NIDA) and other governmental agencies. This lifetime work resulted in diagnostic tools for Parkinson’s Disease, of which several were licensed to local companies for further development.
The Organix family remembers Peter’s leadership providing a unique welcoming workplace with a caring and compassionate work ethic. Peter was a leader who was kind and respectful and who emphasized people above everything else.
A link to his obituary is provided below.
RIP Peter, you will be sorely missed.
https://www.dignitymemorial.com/obituaries/brookline-ma/peter-meltzer-11641783
Organix becomes part of Symeres
On April 26, 2022 was announced that Organix will be a part of Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). As the majority shareholder in Symeres, Keensight Capital has worked together with the management team of the two companies to facilitate this business combination. The resulting business will create a truly differentiated transatlantic offering for the biopharma industry, with significant expertise in molecule design, synthesis, and early stage clinical manufacturing.
Symeres and Organix are highly complementary and the combination unlocks significant strategic value for our customers. Organix represents a high-quality foothold into the US market for Symeres, and Organix broadens the Symeres drug discovery offering into the fast-growing lipids market, addressing mRNA therapeutics and vaccines. Organix management will remain unchanged, the company is led by Dr. Anu Mahadevan, CEO and Dr. Paul Blundell, President.
Dr. Anu Mahadevan, CEO of Organix, says: “We are proud to become part of the Symeres family where we have found a trusted partner that shares our values and business philosophy of strong customer focus. The added expertise that the deal brings will allow Organix to better serve our clients by providing additional access to state-of-the-art cGMP services. We look forward to being a part of this innovative and science-driven organization.”
Symeres is a leading mid-sized European Contract Research Organization for drug discovery and development needs. With over 500 employees operating in the Netherlands, the Czech Republic, and Finland along with a business development office in the US. The company offers best-in-class solutions for drug discovery and drug development for small molecules and beyond. The services span from preclinical hit finding all the way to the delivery of early clinical phase drug substance API. Symeres blends a deep scientific knowledge base with creativity and problem-solving skills to deliver quality results that clients need. For more information please visit: www.symeres.com
To read the full press release click here
September 2019: Organix was awarded an NIH contract for CRO Support for NCATS Medicinal Chemistry for Lead Optimization (N01TR-19-2007).
Day 2: 17th Annual Discovery on Target, Paul Blundell and Anu Mahadevan working the booth and Ravi Ujjinamatada who presented our poster on “Discovery of novel ID1 inhibitors which are based on cannabinoid template to treat late stage cancers”
#BostonDOT19 #drugdiscovery #event #networking #chemistry #cannabinoids
Thank you to everyone who stopped by our booth at MALSI Day on the 27th June. It was great to see you there. Here are a few pictures from the event.
WHAT MAKES ORGANIX SO SUCCESFUL? AN INTERVIEW WITH ANU MAHADEVAN (CEO) AND PAUL BLUNDELL (PRESIDENT)
In June, during a client visit to the Organix facilities, Russ Thomas interviewed Anu Mahadevan (CEO) and Paul Blundell (President) of Organix, our new organization in
Woburn, just outside Boston Massachusetts. Russ wanted to introduce Anu and Paul to the rest of the Symeres family and find out more about them and what makes Organix so successful.